56 Biosimilars In Late-Stage Development Line Up To Challenge Top Biologic Drugs
Executive Summary
Many key biologic drugs, including adalimumab, bevacizumab, rituximab and trastuzumab, are facing biosimilar competition from products that have been either filed or recently approved in Europe, and 56 biosimilars are now at a late stage of clinical development, according to Per Troein of QuintilesIMS.
You may also be interested in...
2017 – Scrip Readers’ Pharma Year In Review
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.
2017 – Scrip Readers’ Pharma Year In Review
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.